SCHEMBL6358200

SCHEMBL6358200

CCOC(=O)CCCC(=O)ON1C(=O)CCC1=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.46
RAB9A P51151 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
BRD4 O60885 1/20 0.40
SMYD3 Q9H7B4 1/20 0.39
TSHR P16473 2/20 0.38
NR1I2 O75469 1/20 0.38
PGR P06401 1/20 0.38
ADORA3 P0DMS8 1/20 0.38
PTGS2 P35354 1/20 0.38
PDE4D Q08499 1/20 0.38
TNF P01375 2/20 0.38
CYP4F2 P78329 1/20 0.38
CYP4A11 Q02928 1/20 0.38
GSK3A P49840 1/20 0.38
GSK3B P49841 1/20 0.38
NAMPT P43490 1/20 0.37
LMNA P02545 1/20 0.37
POLB P06746 1/20 0.37
KDM4E B2RXH2 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17256327 0.95 CYP1A2 (0.44) CYP1A2RAB9AL3MBTL1BRD4TSHR
SCHEMBL14948533 0.93 TSHR (0.43) CYP1A2L3MBTL1TSHRCYP4F2CYP4A11
SCHEMBL22777675 0.88 SMN1; SMN2 (0.36) TSHRADORA3LMNAKMT2ASMN1; SMN2
SCHEMBL34383 0.88 SMN1; SMN2 (0.36) TSHRADORA3LMNAKMT2ASMN1; SMN2
SCHEMBL9978168 0.87 MAPK1 (0.44) L3MBTL1BRD4ALDH1A1KMT2ASMN1; SMN2
SCHEMBL18932208 0.86 DGKA (0.40) CYP1A2RAB9AL3MBTL1BRD4TSHR
SCHEMBL7954092 0.86 DGKA (0.40) RAB9AL3MBTL1BRD4TSHRPOLB
SCHEMBL13627386 0.86 DGKA (0.46) L3MBTL1LMNAALDH1A1GAAKMT2A
SCHEMBL29945244 0.86 SMN1; SMN2 (0.36) TSHRLMNAKMT2ASMN1; SMN2
SCHEMBL4700272 0.84 BRD4 (0.42) CYP1A2RAB9AL3MBTL1BRD4TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170340774-A1 POLETHYLENE GLYCOL HYDROGEL INJECTION SUNBIO INC. (KR) 2017-11-30 US disclosed
US-20140155457-A1 Method of Relieving, Improving, Preventing or Treating Xerostomia SUNBIO INC. (KR) 2014-06-05 US disclosed
US-8729258-B2 Luminescent macrocyclic lanthanide complexes THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-05-20 US disclosed
US-8729258-B2 Luminescent macrocyclic lanthanide complexes THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-05-20 US disclosed
US-20120329174-A1 LUMINESCENT MACROCYCLIC LANTHANIDE COMPLEXES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-12-27 US disclosed
US-20120329174-A1 LUMINESCENT MACROCYCLIC LANTHANIDE COMPLEXES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-12-27 US disclosed
US-8173800-B2 Hydroxy-isophthalamide moieties; antibodies; high stability, luminescence; kits THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-05-08 US disclosed
US-8173800-B2 Hydroxy-isophthalamide moieties; antibodies; high stability, luminescence; kits THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-05-08 US disclosed
US-20080213917-A1 LUMINESCENT MACROCYCLIC LANTHANIDE COMPLEXES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2008-09-04 US disclosed
US-20080213917-A1 LUMINESCENT MACROCYCLIC LANTHANIDE COMPLEXES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2008-09-04 US disclosed
US-20070031498-A1 GEL COMPOSITION FOR CELLULAR ADHESION INHIBITION WRIGHT MEDICAL TECHNOLOGY, INC. 2007-02-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080213917-A1 LUMINESCENT MACROCYCLIC LANTHANIDE COMPLEXES SSB, HACD3, CLTA CYP1A2 4569/4885RAB9A 3711/4885L3MBTL1 66/4885
US-20070031498-A1 GEL COMPOSITION FOR CELLULAR ADHESION INHIBITION CD44, EPCAM, ICAM1 CYP1A2 4770/4885RAB9A 4045/4885L3MBTL1 3636/4885
US-20140155457-A1 Method of Relieving, Improving, Preventing or Treating Xerostomia GLA, LPO, MUC1 CYP1A2 1630/4885RAB9A 1916/4885L3MBTL1 4501/4885
US-20120329174-A1 LUMINESCENT MACROCYCLIC LANTHANIDE COMPLEXES SSB, HACD3, CLTA CYP1A2 4569/4885RAB9A 3711/4885L3MBTL1 66/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.